SCHEMBL6948310

SCHEMBL6948310

CCOC(=O)C(=O)CC(C)(C)c1ccc(I)cc1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
PLIN1 O60240 1/20 0.37
POLB P06746 1/20 0.37
PLIN5 Q00G26 1/20 0.37
ABHD5 Q8WTS1 1/20 0.37
HSD17B2 P37059 1/20 0.36
GAA P10253 3/20 0.36
ALDH1A1 P00352 6/20 0.36
PKM P14618 3/20 0.36
HTT P42858 1/20 0.36
STING1 Q86WV6 1/20 0.36
CNR2 P34972 2/20 0.34
HPGD P15428 2/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3533848 0.88 LMNA (0.39) MAPTMEN1KMT2ALMNAPLIN1
SCHEMBL3531538 0.88 NR1H4 (0.36) MAPTLMNAALDH1A1HTTHPGD
SCHEMBL3533850 0.86 MAPT (0.39) MAPTMEN1KMT2ALMNAPLIN1
SCHEMBL3535929 0.83 NR1H4 (0.37) LMNAGAAHPGD
SCHEMBL3533288 0.82 MEN1 (0.49) MAPTMEN1KMT2ALMNAPLIN1
SCHEMBL5242773 0.78 NR3C1 (0.48)
SCHEMBL4818606 0.78 PTGDR2 (0.42) MAPTMEN1KMT2ALMNAPLIN1
SCHEMBL27670756 0.75 MAPT (0.42) MAPTMEN1KMT2ALMNAPLIN1
SCHEMBL3533487 0.75 PRKCZ (0.41) MAPTKMT2ALMNAGAAALDH1A1
SCHEMBL6170291 0.74 PTGDR2 (0.41) MAPTMEN1KMT2ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203902-A1 Nonsteroidal gestagens SCHERING AKTIENGESELLSCHAFT (DE) 2003-10-30 US disclosed
US-6548534-B2 Nonsteroidal gestagens SCHERING AKTIENGESELLSCHAFT (DE) 2003-04-15 US disclosed
US-20020016365-A1 Nonsteroidal gestagens SCHERING AKTIENGESELLSCHAFT (DE) 2002-02-07 US disclosed
US-6344454-B1 CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-02-05 US disclosed
US-6323199-B1 AROMATIC HETEROCYCLIC HYDROXY AMINES OR AMIDES FOR TREATMENT OF INFLAMMATION SCHERING AKTIENGESELLSCHAFT (DE) 2001-11-27 US disclosed
US-6245804-B1 CONTRACEPTIVES; UROGENITAL DISORDERS SCHERING AKTIENGESELLSCHAFT (DE) 2001-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016365-A1 Nonsteroidal gestagens NR5A1, GPER1, ESR2 MAPT 3996/4885MEN1 1637/4885KMT2A 2678/4885
US-20030203902-A1 Nonsteroidal gestagens GPER1, NR5A1, ESR2 MAPT 4055/4885MEN1 2038/4885KMT2A 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.